Empagliflozin
Cardiomyopathy
Post Graduate Institute of Medical Education and Research, ChandigarhSmall moleculePhase 4 / ApprovedActive
BB
65/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 50/ 100
- Competitive Position
- 95/ 100
Competitive context
8 Active assets in the Cardiomyopathy cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
CARVEDILOL Post Graduate Institute of Medical Education and Research, Chandigarh | Phase 4 | BB |
DESFERRIOXAMINE B Ospedale Microcitemico | Phase 4 | BB |
Deferiprone Ospedale Microcitemico | Phase 4 | BB |
Semaglutide Mayo Clinic | Phase 4 | BB |
Acoramidis Eidos Therapeutics, a BridgeBio company | Phase 3 | BB |
View all 21 →
Same molecule, other indications
Empagliflozin is also rated in:
metabolic dysfunction-associated steatotic liver diseaseActive
BBB
Indicative · Phase 4
73 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →